{
  "id": "d36b4f92c0646f06",
  "title": "Guggenheim Sets $62 Target on Bristol - Myers Squibb Company ( BMY ) After FDA Priority Review",
  "description": "20251217T224500Z",
  "content": "",
  "source": "insidermonkey.com",
  "source_url": "https://www.insidermonkey.com/blog/guggenheim-sets-62-target-on-bristol-myers-squibb-company-bmy-after-fda-priority-review-1661800/",
  "published_at": "20251217T224500Z",
  "fetched_at": "2025-12-18T00:22:47.263985+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.insidermonkey.com/blog/guggenheim-sets-62-target-on-bristol-myers-squibb-company-bmy-after-fda-priority-review-1661800/",
    "url_mobile": "https://www.insidermonkey.com/blog/guggenheim-sets-62-target-on-bristol-myers-squibb-company-bmy-after-fda-priority-review-1661800/?amp=1",
    "title": "Guggenheim Sets $62 Target on Bristol - Myers Squibb Company ( BMY ) After FDA Priority Review",
    "seendate": "20251217T224500Z",
    "socialimage": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/12/11085633/CARM-insidermonkey-1702302991517.jpg",
    "domain": "insidermonkey.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}